Navigation Links
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
Date:12/7/2012

ATLANTA and NES-ZIONA, Israel, Dec. 7, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present preclinical data on its long-acting clotting Factor VIIa (Factor Vlla-CTP) at the 54th Annual Meeting of the American Society of Hematology (ASH).  The data will be discussed by Dr. Gili Hart, Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program, in an oral poster presentation on December 8, 2012.  PROLOR's Factor VIIa-CTP is in advanced preclinical development for the treatment of hemophilia.

Top-line results of the Factor Vlla-CTP studies have been previously reported by PROLOR. The results show that when compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated a markedly enhanced pharmacokinetic profile and increased exposure, as evidenced by a prolonged hemostatic effect and improved recovery, which is a measure of clotting activity.  Compared to commercially available Factor VIIa, Factor VIIa-CTP in hemophilic mice demonstrated superior thrombin generation parameters, and it resulted in greater survival of the subjects.  In these studies, the specific activity of Factor VIIa-CTP was comparable to commercial Factor VIIa.  The study data also show that administration of Factor Vlla-CTP by subcutaneous injection resulted in improved bioavailability and prolonged exposure compared to intravenous administration of Factor Vlla-CTP.

PROLOR CEO Dr. Abraham Havron commented, "The ASH Annual Meeting is the largest and most prominent gathering of hematology experts in the world.  In preclinical studies our long-acting clotting factors have demonstrated the potential to significantly improve both the prophylactic and on-demand treatment of patients with hemophilia, and we welcome the opportunity to share these promising data with leading hematology researchers."

Dr. Hart will presen
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GenWay Biotech Appoints New Vice President of Custom/OEM
2. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Obamacare Ruling, Other Pivotal News Rocks Biotech Sector in June
8. Tougher Times May be Ahead for Biotechs: 1H12 Fundraising Slows
9. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Jan. 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Phase 1 proof-of-concept and local tolerability study of HTI-501 ... 8th World Congress of the International Academy of Cosmetic ... commencement of the Phase 2 portion of the clinical ...
... LAKES, N.J., Jan. 31, 2012 The Board of Directors of ... declared a quarterly dividend of 45 cents per common share, payable ... 2012. The indicated annual dividend rate is $1.80 per share. ... is a leading global medical technology company that develops, manufactures and ...
Cached Medicine Technology:HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:9/30/2014)... the spiraling costs of drugs paid for by the ... meaningful impact on cancer chemotherapy drug costs, say a ... Oncology published online today. , "We looked at ... cancers, and did not find a substantial change in ... the recent Medicare law in 2005," says the study,s ...
(Date:9/30/2014)... Centers (FQHCs) granted new patient appointments to Medicaid ... other primary care practices (non-FQHCs), in addition to ... a new 10-state University of Pennsylvania study published ... Using data from a previous "secret shopper" study ... that FQHCs community health clinics that receive ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... 30, 2014 The American Diabetes ... help diabetics curb their sweet tooth, but the most ... this September, suggests that zero-calorie sweeteners may actually be ... , The Weizmann Institute of Science in Israel ... sweeteners to mice, the mice developed glucose intolerance. They ...
(Date:9/30/2014)... September 30, 2014 With the ... strains emerging every day, it’s a perfect time ... The EnviroShield system is an electro-static disinfectant delivery ... to surface normally missed with spray-on disinfectant applicators. ... that adds an electrostatic negative charge to the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2
... (NEWARK, N.J., March 18, 2008) Julia Duane Quinlan, ... remove her daughter from a respirator changed the use ... annual Joe and Julia Quinlan Award to Dr. John ... Rev. Charles J. Hudson and Margaret J. Coloney from ...
... than 30% Enrolled in Consumer-Driven Plans Have Household ... Enrollment in,consumer-driven and high-deductible health plans increased ... of the overall insurance market, according,to the third ... Enrollment in consumer-driven plans with a tax-advantaged,account was ...
... Inc. (NYSE: BRL ), today confirmed that ... Deutsche Bank, acting as PLIVA,s GDR,Depositary, on termination ... June 19, 2008 ("Termination Date"). Once the Deposit,Agreement ... from the London,Stock Exchange ("LSE"), a process that ...
... Internal Controls and Procedures Improvements, Corporate, Governance Enhancements, ... Va., March 18 Sunrise Senior Living,Inc. (NYSE: ... New York Stock,Exchange ("NYSE") that the Company did not ... filing its 2006 Form 10-K. The Company also,announced the ...
... severe inherited metabolic disorder, which is associated with ... cardiac manifestations in Wilson,s disease include arrhythmias and ... Ihtisas Hospital and in Ankara University Faculty of ... non-invasive marker of intra-atrial conduction disturbance in patients ...
... who experience military combat obviously endure extreme stress, and ... of post-traumatic stress disorder, or PTSD. PTSD is ... However, as researcher Roger Pitman explains, Although it ... by the traumatic event, it is also possible that ...
Cached Medicine News:Health News:Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 3Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 4Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 3Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 2Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 5Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 6Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 7Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 8Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 9Health News:How does P wave dispersion change in patients with Wilson's disease? 2Health News:Does stress damage the brain? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: